Evidence map›Paper›PMID 18714386›Full record

ArticlePloS one2008

DNA-free recombinant SV40 capsids protect mice from acute renal failure by inducing stress response, survival pathway and apoptotic arrest.

Veronika Butin-Israeli, Dotan Uzi, Mahmoud Abd-El-Latif, Galina Pizov, Arieh Eden, Yosef S Haviv, Ariella Oppenheim

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Veronika Butin-IsraeliDepartment of Hematology, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Dotan Uzi
Mahmoud Abd-El-Latif
Galina Pizov
Arieh Eden
Yosef S Haviv
Ariella Oppenheim
Hebrew University of Jerusalem · ILCarmel Medical Center · IL

Funding

Genetics of SV40 Entry and Minichromosome TransportR01CA100479 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI NORKIN, LEONARD C. · 2004 to 2008
$1.0M
NCI NIH HHS R01 CA100479NCI NIH HHS R01 CA 100479-01A2
6 · The paper itself

Abstract

Viruses induce signaling and host defense during infection. Employing these natural trigger mechanisms to combat organ or tissue failure is hampered by harmful effects of most viruses. Here we demonstrate that SV40 empty capsids (Virus Like Particles-VLPs), with no DNA, induce host Hsp/c70 and Akt-1 survival pathways, key players in cellular survival mechanisms. We postulated that this signaling might protect against organ damage in vivo. Acute kidney injury (AKI) was chosen as target. AKI is critical, prevalent disorder in humans, caused by nephrotoxic agents, sepsis or ischemia, via apoptosis/necrosis of renal tubular cells, with high morbidity and mortality. Systemic administration of VLPs activated Akt-1 and upregulated Hsp/c70 in vivo. Experiments in mercury-induced AKI mouse model demonstrated that apoptosis, oxidative stress and toxic renal failure were significantly attenuated by pretreatment with capsids prior to the mercury insult. Survival rate increased from 12% to >60%, with wide dose response. This study demonstrates that SV40 VLPs, devoid of DNA, may potentially be used as prophylactic agent for AKI. We anticipate that these finding may be projected to a wide range of organ failure, using empty capsids of SV40 as well as other viruses.

Indexed as

Acute Kidney InjuryAnimalsApoptosisCapsid ProteinsCell LineDisease Models, AnimalDNA, ViralHaplorhiniHumansKidneyMiceNecrosisSimian virus 40Capsid ProteinsDNA, Viral

Identifiers

PMID18714386
PMCPMC2515219
OpenAlexW2095164621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.